REPORT DIFF

Catalyst Pharmaceuticals — what changed

2026-08-11 → 2026-08-19 · 6 changed lines · numbers highlighted

3. Financial Analysis (6 changed lines)

− | **Z-Score** | **5.01** | **6.04** | **6.54** |

+ | **Z-Score** | **3.84** | **4.46** | **4.78** |

− **Interpretation.** The Altman Z-Score placed Catalyst firmly in the safe zone throughout and moving further into it — 5.01 in FY2023, 6.04 in FY2024 and 6.54 in FY2025, well above the 2.99 safe-zone threshold with no drift toward a boundary. The score is unsurprising given the balance-sheet facts already established: a debt-free capital structure lifts the equity-to-liabilities term, a large cash

+ **Interpretation.** The Altman Z-Score placed Catalyst firmly in the safe zone throughout and moving further into it — 3.84 in FY2023, 4.46 in FY2024 and 4.78 in FY2025, well above the model's 2.90 safe-zone threshold with no drift toward a boundary. The score is unsurprising given the balance-sheet facts already established: a debt-free capital structure lifts the equity-to-liabilities term, a la